These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

813 related articles for article (PubMed ID: 30339291)

  • 1. Sight-threatening Graves' orbitopathy: Twenty years' experience of a multidisciplinary thyroid-eye outpatient clinic.
    Tramunt B; Imbert P; Grunenwald S; Boutault F; Caron P
    Clin Endocrinol (Oxf); 2019 Jan; 90(1):208-213. PubMed ID: 30339291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical characteristics of dysthyroid optic neuropathy].
    Elyashiv S; Skaat A; Ben Simon G; Huna-Baron R
    Harefuah; 2015 Feb; 154(2):98-102, 137. PubMed ID: 25856861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete recovery of visual acuity as the main goal of treatment in patients with dysthyroid optic neuropathy.
    Miśkiewicz P; Rutkowska B; Jabłońska A; Krzeski A; Trautsolt-Jeziorska K; Kęcik D; Milczarek-Banach J; Pirko-Kotela K; Samsel A; Bednarczuk T
    Endokrynol Pol; 2016; 67(2):166-73. PubMed ID: 26884288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical features of dysthyroid optic neuropathy: a European Group on Graves' Orbitopathy (EUGOGO) survey.
    McKeag D; Lane C; Lazarus JH; Baldeschi L; Boboridis K; Dickinson AJ; Hullo AI; Kahaly G; Krassas G; Marcocci C; Marinò M; Mourits MP; Nardi M; Neoh C; Orgiazzi J; Perros P; Pinchera A; Pitz S; Prummel MF; Sartini MS; Wiersinga WM;
    Br J Ophthalmol; 2007 Apr; 91(4):455-8. PubMed ID: 17035276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors for significant 6-month recovery in dysthyroid optic neuropathy in a tertiary center: A series of 69 eyes in 38 patients.
    Vermot-Desroches V; Thia-Soui-Tchong K; Raymond P; Filip A; Orgiazzi J; Jouanneau E; Froment Tilikete C; Borson-Chazot F; Manet R; Abeillon Du Payrat J
    Ann Endocrinol (Paris); 2023 Aug; 84(4):430-439. PubMed ID: 37086950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural history of graves' orbitopathy after treatment.
    Menconi F; Leo M; Sabini E; Mautone T; Nardi M; Sainato A; Sellari-Franceschini S; Vitti P; Marcocci C; Marinò M
    Endocrine; 2017 Aug; 57(2):226-233. PubMed ID: 27709471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dysthyroid optic neuropathy: evaluation and management.
    Dolman PJ
    J Endocrinol Invest; 2021 Mar; 44(3):421-429. PubMed ID: 32729049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and Visual Outcomes of Dysthyroid Optic Neuropathy After Surgical Orbital Decompression.
    Currò N; Guastella C; Pirola G; Calonghi B; Bottari de Castello A; Fazio MC; di Benedetto S; Minorini V; Daga M; Contarino A; Muller I; Arosio M; Viola F; Pignataro L; Salvi M
    Thyroid; 2023 Jun; 33(6):743-751. PubMed ID: 37140534
    [No Abstract]   [Full Text] [Related]  

  • 9. Balanced medial-lateral wall vs selective 3-wall orbital decompression for sight-threatening Graves's orbitopathy: a clinical retrospective cohort study from 2016 to 2022.
    Tian P; Zeng P; Zhang H; Liang J; Li E; Ma Y; Zou H; Wang M; Xiang L
    Eur Arch Otorhinolaryngol; 2024 Sep; 281(9):4807-4815. PubMed ID: 38613579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in peripapillary blood vessel density in Graves' orbitopathy after orbital decompression surgery as measured by optical coherence tomography angiography.
    Lewis KT; Bullock JR; Drumright RT; Olsen MJ; Penman AD
    Orbit; 2019 Apr; 38(2):87-94. PubMed ID: 29517388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Management of Graves' orbitopathy: evidence-based recommendations].
    Ponto KA; Pitz S; Mann WJ; Weber MM; Pfeiffer N; Kahaly GJ
    Dtsch Med Wochenschr; 2009 Dec; 134(49):2521-4. PubMed ID: 19941237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tocilizumab as first treatment option in optic neuropathy secondary to Graves' orbitopathy.
    Pascual-Camps I; Molina-Pallete R; Bort-Martí MA; Todolí J; España-Gregori E
    Orbit; 2018 Dec; 37(6):450-453. PubMed ID: 29420104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy.
    Bartalena L; Kahaly GJ; Baldeschi L; Dayan CM; Eckstein A; Marcocci C; Marinò M; Vaidya B; Wiersinga WM;
    Eur J Endocrinol; 2021 Aug; 185(4):G43-G67. PubMed ID: 34297684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Orbital decompression in Graves' orbitopathy: efficacy and safety.
    Goh MS; McNab AA
    Intern Med J; 2005 Oct; 35(10):586-91. PubMed ID: 16207257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal management of Graves orbitopathy: a multidisciplinary approach.
    Soeters MR; van Zeijl CJ; Boelen A; Kloos R; Saeed P; Vriesendorp TM; Mourits MP
    Neth J Med; 2011; 69(7):302-8. PubMed ID: 21934174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization of the treatment of moderate to severe and active thyroid orbitopathy considering the recommendations of the European Group on Graves' Orbitopathy (EUGOGO) [Optymalizacja leczenia umiarkowanej do ciężkiej i aktywnej orbitopatii tarczycowej z uwzględnieniem zaleceń European Group on Graves' Orbitopathy (EUGOGO)].
    Nowak M; Marek B; Kos-Kudła B; Siemińska L; Londzin-Olesik M; Głogowska-Szeląg J; Nowak W; Kajdaniuk D
    Endokrynol Pol; 2022; 73(4):756-777. PubMed ID: 36059167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of Graves ophthalmopathy - 2022 update.
    Jiskra J
    Cas Lek Cesk; 2022; 161(5):198-206. PubMed ID: 36443100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orbital radiotherapy plus three-wall orbital decompression in a patient with rare ocular manifestations of thyroid eye disease: case report.
    Zhang S; Wang Y; Zhong S; Liu X; Huang Y; Fang S; Zhuang A; Li Y; Sun J; Zhou H; Fan X
    BMC Endocr Disord; 2018 Feb; 18(1):7. PubMed ID: 29409479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intraocular pressure lowering effect of orbital decompression is related to increased venous outflow in Graves orbitopathy.
    Onaran Z; Konuk O; Oktar SÖ; Yücel C; Unal M
    Curr Eye Res; 2014 Jul; 39(7):666-72. PubMed ID: 24502333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single-center analysis of visual outcomes and associated factors after intravenous methylprednisolone treatment for dysthyroid optic neuropathy.
    Kemchoknatee P; Tangon D; Srisombut T
    BMC Ophthalmol; 2023 Jan; 23(1):32. PubMed ID: 36690985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.